Overview |
bs-3582R-Cy7 |
TIF1 gamma Polyclonal Antibody, Cy7 Conjugated |
FCM, IF(IHC-P), IF(IHC-F), IF(ICC) |
Human, Mouse, Rat |
Dog, Cow, Pig, Horse, Chicken |
Specifications |
Cy7 |
Rabbit |
KLH conjugated synthetic peptide derived from human TIF1 gamma |
981-1127/1127 |
Polyclonal |
IgG |
1ug/ul |
Purified by Protein A. |
Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
Target |
51592 |
Q9UPN9 |
Nucleus |
ECTO; PTC7; RFG7; TF1G; TIF1G; TIFGAMMA; TIF1GAMMA; E3 ubiquitin-protein ligase TRIM33; Ectodermin homolog; RET-fused gene 7 protein; Protein Rfg7; Transcription intermediary factor 1-gamma; TIF1-gamma; Tripartite motif-containing protein 33; TRIM33; KIAA1113 |
Acts as an E3 ubiquitin-protein ligase. Promotes SMAD4 ubiquitination, nuclear exclusion and degradation via the ubiquitin proteasome pathway. According to PubMed:16751102, does not promote a decrease in the level of endogenous SMAD4. May act as a transcriptional repressor. Inhibits the transcriptional response to TGF-beta/BMP signaling cascade. Plays a role in the control of cell proliferation. Its association with SMAD2 and SMAD3 stimulates erythroid differentiation of hematopoietic stem/progenitor (By similarity). Monoubiquitinates SMAD4 and acts as an inhibitor of SMAD4-dependent TGF-beta/BMP signaling cascade (Monoubiquitination of SMAD4 hampers its ability to form a stable complex with activated SMAD2/3 resulting in inhibition of TGF-beta/BMP signaling cascade). |
Application Dilution |
FCM |
1:20-100 |
IF(IHC-P) |
1:50-200 |
IF(IHC-F) |
1:50-200 |
IF(ICC) |
1:50-200 |